Malta - englanti - Medicines Authority

health house pharma ltd t/as p&d pharmaceuticals ltd 38 woolmer way, bordon, hampshire, gu35 9q, united kingdom - budesonide - dispersible tablet - budesonide 0.02 mg/ml - antidiarrheals, intestinal antiinflammatory/antiinfective agents

Malta - englanti - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - budesonide - hard capsule - budesonide 3 mg - antidiarrheals, intestinal antiinflammatory/antiinfective agents

Arabiemiirikunnat - englanti - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

50's bottle -

Arabiemiirikunnat - englanti - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

alhayat pharmaceuticals france - 100's bottle - capsule - 3mg/capsule (prolonged release) - gastrointestinal system-chronic bowel disorders

Jordania - englanti - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع ادوية شاوي و رشيدات و مسنات - shawi & rushedat drug store - budesonide 2.3 mg - 2.3 mg

Jordania - englanti - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة مستودع أدوية أوتار - awtar pharmaceutical co - budesonide 3 mg - 3 mg

Jordania - englanti - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة مستودع أدوية أوتار - awtar pharmaceutical co - budesonide 3 mg - 3 mg

Yhdysvallat - englanti - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - budesonide (unii: q3oks62q6x) (budesonide - unii:q3oks62q6x) - budesonide 3 mg - budesonide capsules is indicated for the treatment of mild to moderate active crohn's disease involving the ileum and/or the ascending colon. pediatric use information is approved for perrigo pharma international dac’s entocort ec (budesonide) capsules. however, due to perrigo pharma international dac’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. budesonide capsules is indicated for the maintenance of clinical remission of mild to moderate crohn’s disease involving the ileum and/or the ascending colon for up to 3 months in adults. budesonide capsules is contraindicated in patients with hypersensitivity to budesonide or any of the ingredients of budesonide capsules. serious hypersensitivity reactions, including anaphylaxis have occurred [see adverse reactions (6.2) ]. risk summary limited published studies report on the use of budesonide in pregnant women; however, the data are insufficient to inform a drug-associated risk for major birth defects and miscarr

Yhdysvallat - englanti - NLM (National Library of Medicine)

alvogen, inc. - budesonide (unii: q3oks62q6x) (budesonide - unii:q3oks62q6x) - budesonide 3 mg - budesonide capsules (enteric coated)  are indicated for the treatment of mild to moderate active crohn's disease involving the ileum and/or the ascending colon. pediatric use information is approved for perrigo pharma international dac’s entocort ec (budesonide) capsules. however, due to perrigo pharma international dac’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. budesonide capsules (enteric coated) are indicated for the maintenance of clinical remission of mild to moderate crohn's disease involving the ileum and/or the ascending colon for up to 3 months in adults. budesonide capsules (enteric coated) are contraindicated in patients with hypersensitivity to budesonide or any of the ingredients of budesonide capsules (enteric coated). serious hypersensitivity reactions, including anaphylaxis have occurred  [see adverse reactions (6.2)]. risk summary limited published studies report on the use of budesonide in pregnant women; however, the data are insuffici

Yhdysvallat - englanti - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - budesonide (unii: q3oks62q6x) (budesonide - unii:q3oks62q6x) - budesonide 3 mg - budesonide capsules (enteric coated) are indicated for the treatment of mild to moderate active crohn's disease involving the ileum and/or the ascending colon. pediatric use information is approved for perrigo pharma international dac’s entocort ec (budesonide) capsules. however, due to perrigo pharma international dac’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. budesonide capsules (enteric coated) are indicated for the maintenance of clinical remission of mild to moderate crohn's disease involving the ileum and/or the ascending colon for up to 3 months in adults. budesonide capsules (enteric coated) are contraindicated in patients with hypersensitivity to budesonide or any of the ingredients of budesonide capsules (enteric coated). serious hypersensitivity reactions, including anaphylaxis have occurred [see adverse reactions (6.2)]. limited published studies report on the use of budesonide in pregnant women; however, the data are insufficient to inform a